EGFR and non-small cell lung carcinoma: In this context, the phase III ADAURA trial demonstrated the significant benefit of adjuvant osimertinib versus placebo in terms of disease-free survival (DFS) in patients with stage IB-IIIA epidermal growth factor receptor (EGFR) mutation-positive NSCLC, regardless of the use of adjuvant chemotherapy.